Doxazosin Added to Single‐Drug Therapy in Hypertensive Patients with Benign Prostatic Hypertrophy

Abstract

H ypertension is one of the most common chronic diseases in the developed countries. 1,2 Benign prostatic hyperplasia (BPH) is one of the most frequent and bothersome health problems in males >50 years of age; more than 50% of males >60 suffer from prostatism. 3 In the United States, treatment of BPH represents approximately 25% of the urologists' total workload. 4 According to Beurton, 5 microscopic evidence of BPH is present in 100% of males at 80 years of age. The percentage of BPH at autopsy is increasing each year after 40 years of age, 6 amounting to >70% after 60 years of age in most studies. [7][8][9] This phenomenon also extends to clinical symptoms, 10 although at a lower rate (20% at 60 years; 43% at >80 years). Rates of BPH and symptoms may vary according to regions and culture. In an epidemiologic study carried out in Spain, 11 the prevalence of symptomatic BPH, according to In-

Treatment of Benign Prostatic Hyperplasia in Hypertensive Men

“…Because α 1 blocker therapy has been used independently to treat patients with hypertension and to treat patients with BPH, some clinicians have proposed using α 1 -blocker monotherapy for the treatment of concomitant hypertension and BPH; this strategy has been tested in a number of clinical trials. 50,51 Current clinical practice guidelines, however, would not favor α 1 -blocker-based therapy for the treatment of patients with hypertension; consequently, α 1 -blocker monotherapy should no longer be recommended as initial treatment of hypertension with comorbid BPH. The JNC 7 has proposed diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β blockers, or calcium…”